Harmony Biosciences Holdings, Inc.
HRMY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HRMY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HRMY
Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, with its approved product WAKIX (pitolisant) for adult narcolepsy and a pipeline of candidates in clinical development.
Key risk: Single product reliance
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 11 clinical trials · 8 catalysts for Harmony Biosciences Holdings, Inc..
Similar companies
Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, with its approved product WAKIX (pitolisant) for adult narcolepsy and a pipeline of candidates in clinical development.
- WAKIX (pitolisant) net revenue was $714.7 million in 2024, a 23% increase year-over-year [sec · filed 2025-04-04].
- As of June 30, 2026, the company reported cash & equivalents of $550.0M, total revenue of $261.3M, net income of $75.4M, shareholders' equity of $870.2M, and total debt of $174.0M [sec].
- The company is advancing multiple pipeline programs including BP-205, EPX-100, Pitolisant GR and HD, and HBS-301, with several Phase 3 topline readouts expected between 2026 and 2031 [sec_mda · as of 2026-08-04].
- Research and development expenses increased significantly in the first half of 2026, driven by clinical trial progress and in-process R&D charges from licensing agreements [sec_mda · as of 2026-08-04].
What works
- WAKIX has demonstrated sustained revenue growth, with net revenue increasing 23% year-over-year to $714.7 million in 2024, indicating strong commercial durability [sec · filed 2025-04-04].
- The company has a robust cash position of $550.0M as of June 30, 2026, providing financial flexibility to fund ongoing pipeline development [sec].
- Harmony is advancing a diversified pipeline of product candidates targeting multiple neurological indications, with several Phase 3 trials underway [sec_mda · as of 2026-08-04].
What to weigh
- The company is heavily reliant on a single product, WAKIX, for its revenue, with no other approved products to diversify commercial risk [sec · filed 2025-04-04].
- Research and development costs are rising, with a $24.7 million increase in expenses for BP-205, EPX-100, and Pitolisant GR and HD in the first half of 2026, and additional IPR&D charges from licensing agreements [sec_mda · as of 2026-08-04].
- The development timeline and costs for pipeline candidates are uncertain, and the company acknowledges it cannot reasonably estimate the nature, timing, or costs to complete development for additional indications [sec_mda · as of 2026-08-04].
- WAKIX faces patent expiry in 2031, which could expose the product to generic competition and impact future revenue [catalyst_timeline].
From the filings
Quoted directly from source documents.
WAKIX revenue growth in 2024
“We saw another solid year of growth for WAKIX in 2024 with net revenue of $714.7 million, representing an increase of 23% year over year.”
SEC filings · April 4, 2025
Uncertainty in development costs and timelines
“At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any additional indications for pitolisant or other product candidates that we move forward for regulatory approval.”
SEC MD&A · August 4, 2026
Increase in R&D expenses for pipeline programs
“The increase for the six months ended June 30, 2026, was primarily driven by a combined $24.7 million increase in research and development expenses for BP-205, EPX-100, and Pitolisant GR and HD as we progressed clinical trials and manufacturing”
SEC MD&A · August 4, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · bp1.15205 — Phase 2 readout for bp1.15205 will provide initial efficacy and safety data in the targeted indication.
- 2027-11-01 · Phase3_Topline · hbs-301 — First Phase 3 topline for HBS-301 in Parkinson's disease; results will inform registration potential.
- 2028-04-01 · Phase3_Topline · pitolisant — Phase 3 topline for pitolisant in Prader-Willi syndrome; outcome critical for label expansion.
- 2028-10-01 · Phase3_Topline · hbs-301 — Second Phase 3 topline for HBS-301; consistency across trials will be key for regulatory submission.
- 2029-05-01 · Phase3_Topline · epx-100 — Phase 3 topline for EPX-100 in Dravet syndrome; data will determine if it can become a new treatment option.
- 2029-11-01 · Phase3_Topline · clemizole — Phase 3 topline for clemizole HCl as adjunctive therapy in Dravet syndrome; results will clarify its efficacy profile.
- 2030-08-01 · Phase3_Topline — Open-label safety study of pitolisant in Prader-Willi syndrome; will support long-term safety data for regulatory filings.
- 2031-06-21 · Patent_Expiry · WAKIX — Patent/exclusivity expiry for WAKIX; could allow generic competition and impact revenue.
Risks & what to watch (4)›
Key risks
- Single product reliance — All current revenue depends on WAKIX; no other approved products to offset potential decline [sec · filed 2025-04-04].
- Pipeline development uncertainty — Cannot estimate timing or costs to complete development for additional indications [sec_mda · as of 2026-08-04].
- Rising R&D costs — R&D expenses increased $24.7M in H1 2026 plus IPR&D charges from licensing deals [sec_mda · as of 2026-08-04].
- Patent expiry risk — WAKIX patent/exclusivity expires in 2031, opening door to generic competition [catalyst_timeline].
What to watch
- Phase 2 topline data for bp1.15205 expected by end of 2026 [catalyst_timeline].
- Phase 3 topline results for HBS-301 in Parkinson's disease (first readout in November 2027) [catalyst_timeline].
- Phase 3 topline data for pitolisant in Prader-Willi syndrome (April 2028) [catalyst_timeline].
- Progress of EPX-100 and clemizole trials for Dravet syndrome (Phase 3 topline in 2029) [catalyst_timeline].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Harmony Biosciences Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Harmony Biosciences Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.37 · 1% dilution
Lead: Approved
4 candidates
8 upcoming, next in ~123d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
309
Total value held
$1.49B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,070,035 | $198.0M |
| vanguard capital management llc | 4,204,630 | $117.8M |
| fmr llc | 3,157,639 | $88.4M |
| vanguard portfolio management llc | 2,714,353 | $76.0M |
| american century companies inc | 2,105,179 | $59.0M |
| dimensional fund advisors lp | 2,076,510 | $58.2M |
| state street corp | 1,784,362 | $50.0M |
| armistice capital, llc | 1,624,000 | $45.5M |
| arrowstreet capital, limited partnership | 1,382,113 | $38.7M |
| geode capital management, llc | 1,322,720 | $37.1M |
Showing top 10 of 309 institutional holders of Harmony Biosciences Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 16.9%
- Days to cover
- 10.7
- Shares short
- 7,290,999
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HRMY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Harmony Biosciences Holdings, Inc.?
Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neurological diseases, with its approved product WAKIX (pitolisant) for adult narcolepsy and a pipeline of candidates in clinical development.
What is Harmony Biosciences Holdings, Inc.'s lead drug candidate?
Harmony Biosciences Holdings, Inc.'s most advanced tracked candidate is EPX-100 (Phase 3) for Developmental and epileptic encephalopathies (DEEs), specifically Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS).
What is Harmony Biosciences Holdings, Inc.'s next catalyst?
Harmony Biosciences Holdings, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: bp1.15205" — expected December 31, 2026.
Who is the CEO of Harmony Biosciences Holdings, Inc.?
Dr. Jeffrey M. Dayno M.D. is the chief executive officer of Harmony Biosciences Holdings, Inc. (HRMY).
Where is Harmony Biosciences Holdings, Inc. headquartered?
Harmony Biosciences Holdings, Inc. (HRMY) is headquartered in Plymouth Meeting, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.